Trial · NCT02789813
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in performance in Behavioral Approach Test (BAT) in real-life (in vivo) | Baseline (visit 1: 7-21 days before visit 2: intervention) and follow up (visit 3: 90 days after visit 2: intervention | |
| Secondary | Change in performance in BAT in virtual reality (in virtuo) | Baseline (visit 1: 7-21 days before visit 2: intervention) and follow up (visit 3: 90 days after visit 2: intervention | |
| Secondary | Change in subjective reactions in BAT in virtual reality (in virtuo) | Baseline (visit 1: 7-21 days before visit 2: intervention) and follow up (visit 3: 90 days after visit 2: intervention | |
| Secondary | Change in psychophysiological reactions in BAT in virtual reality (in virtuo) | Baseline (visit 1: 7-21 days before visit 2: intervention) and follow up (visit 3: 90 days after visit 2: intervention | |
| Secondary | Change in subjective reactions to fear-related picture cue presentation quantified by visual analog scales (VAS) for valence, arousal and fear | Baseline (visit 1: 7-21 days before visit 2: intervention) and follow up (visit 3: 90 days after visit 2: intervention | |
| Secondary | Change in psychophysiological reactions to fear-related picture cue presentation quantified by electrodermal activity (EDA), heart rate (HR), startle response | Baseline (visit 1: 7-21 days before visit 2: intervention) and follow up (visit 3: 90 days after visit 2: intervention | |
| Secondary | Performance in working and recognition memory of pictures task | Follow up (visit 3: 90 days after visit 2: intervention) | |
| Secondary | Valence, arousal, and mood ratings of pictures of working and recognition memory of pictures task | Follow up (visit 3: 90 days after visit 2: intervention) | |
| Secondary | Change in strength of phobic fear quantified by self-report questionnaires | Baseline (7-21 days before visit 2: intervention), intervention (visit 2: 7-21 days after visit 1: baseline) and follow up (visit 3: 90 days after visit 2: intervention) | |
| Secondary | Change in mood and state-anxiety quantified by self-report questionnaires | Baseline (7-21 days before visit 2: intervention), intervention (visit 2: 7-21 days after visit 1: baseline) and follow up (visit 3: 90 days after visit 2: intervention) | |
| Secondary | Change in performance during exposure in virtuo quantified by eye tracking | Intervention (visit 2: 7-21 days after visit 1: baseline) | |
| Secondary | Change in subjective reactions during exposure in virtuo quantified by subjective units of discomfort (SUD) ratings | Intervention (visit 2: 7-21 days after visit 1: baseline) | |
| Secondary | Change in psychophysiological reactions during exposure in virtuo quantified by EDA and HR | Intervention (visit 2: 7-21 days after visit 1) | |
| Secondary | Change in clinical relevance of phobic symptoms measured by Diagnostic Interview for Psychiatric Disorders (DIPS), section for specific phobia | Baseline (visit 1: 7-21 days before visit 2: intervention) and follow up (visit 3: 90 days after visit 2: intervention) | |
| Other | Adverse Events | Baseline (7-21 days before visit 2: intervention), intervention (visit 2: 7-21 days after visit 1: baseline) and follow up (visit 3: 90 days after visit 2: intervention) | |
| Other | Blood pressure | Baseline (7-21 days before visit 2: intervention), intervention (visit 2: 7-21 days after visit 1: baseline) and follow up (visit 3: 90 days after visit 2: intervention) | |
| Other | Heart rate | Baseline (7-21 days before visit 2: intervention), intervention (visit 2: 7-21 days after visit 1: baseline) and follow up (visit 3: 90 days after visit 2: intervention) | |
| Other | VAS of headache, stomach pain, nausea, fatigue, dizziness, drowsiness muscle fatigue, and motivation. | Baseline (7-21 days before visit 2: intervention), intervention (visit 2: 7-21 days after visit 1: baseline) and follow up (visit 3: 90 days after visit 2: intervention) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02789813/registered